Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | USP9X | Q93008 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597018 | 0.87 | AKT1 (0.33) | USP9X | |
| SCHEMBL596988 | 0.87 | GRIN2A (0.39) | GRIN1GRIN2AGRIN2BMMP13LMNA | |
| SCHEMBL10285991 | 0.87 | S1PR1 (0.36) | GRIN1GRIN2AGRIN2BS1PR1S1PR3 | |
| SCHEMBL597589 | 0.85 | MMP13 (0.35) | GRIN1GRIN2AGRIN2BMMP13POLB | |
| SCHEMBL597835 | 0.84 | PSEN1 (0.38) | GRIN1GRIN2AMMP13LMNA | |
| SCHEMBL597072 | 0.83 | MMP13 (0.35) | GRIN1GRIN2AGRIN2BMMP13LMNA | |
| SCHEMBL596923 | 0.82 | METAP2 (0.36) | GRIN1GRIN2AMMP13POLB | |
| SCHEMBL596328 | 0.82 | P2RX7 (0.35) | GRIN1GRIN2AMMP13 | |
| SCHEMBL596896 | 0.81 | MMP13 (0.33) | GRIN1GRIN2AGRIN2BMMP13 | |
| SCHEMBL597108 | 0.80 | CFTR (0.39) | GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114886-B2 | Pyridylmethylsulfone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8114886-B2 | Pyridylmethylsulfone derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20090149439-A1 | PYRIDYLMETHYSULFONE DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| US-20090149439-A1 | PYRIDYLMETHYSULFONE DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1867636-A1 | PYRIDYLMETHYLSULFONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149439-A1 | PYRIDYLMETHYSULFONE DERIVATIVE | APP, IAPP, BACE1 | GRIN1 1289/4885GRIN2A 1776/4885GRIN2B 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.